<DOC>
	<DOCNO>NCT01664663</DOCNO>
	<brief_summary>The purpose study examine valu individually dose escalate radiotherapy compare standard dose radiotherapy combine standard concomitant chemotherapy patient locally advance non small cell lung cancer ( stage III ) good performance status .</brief_summary>
	<brief_title>Phase II Randomized Study Locally Advanced NSCLC Escalated Dose Individual Basis Treatment With Radiochemotherapy</brief_title>
	<detailed_description>This open label , multicentre phase II trial individually escalate radiotherapy 84 Gy due normal tissue dose constraint combine standard concurrent chemotherapy ( cisplatin-vinorelbine ) compare standard dose radiotherapy ( 68 Gy ) combine chemotherapy . There restriction due lung function , performance status pre-treatment weight loss . The main endpoint progression free survival additional endpoint local control , overall survival , toxicity quality life relapse pattern .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histological cytological diagnosis NSCLC stage IIIAB . Nonresectable medically inoperable patient . No prior chemo radiotherapy NSCLC . PS 01 . FEV1 &gt; 1 l &gt; 40 % CO diffusion capacity &gt; 40 % . Patient compliance geographic proximity allow adequate followup . Adequate bone marrow reserve : WBCC &gt; 3.0 , platelet &gt; 100 , haemoglobin &gt; 100 . Written inform concent . Effective use contraception . Excessive weight loss within 6 month ( &gt; 10 % ) . Supraclavicular node . Apical tumorspancoast . T4 tumor separate manifestation different lobe . Evidence active serious infection . Inadequate liver function . Inadequate kidney function . Pregnancy . Breast feeding . Serious concomitant systemic disorder . Second primary malignancy last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Normal tissue constraint</keyword>
	<keyword>Locally advanced disease</keyword>
	<keyword>Good performance status</keyword>
</DOC>